Breakthrough Drug Extends Lifespan in Lung Cancer Battle

An experimental drug, ivonescimab, developed by Akeso, extended the life of patients with advanced squamous non-small cell lung cancer by 15% more than BeOne Medicines' Tevimbra. The Chinese study noted a significant reduction in the risk of death, sparking hope for a new standard in treatment.

An innovative drug known as ivonescimab, created by China-based Akeso, showed promising results in extending patients' lives by 15% compared to BeOne Medicines' Tevimbra in a study focused on advanced squamous non-small cell lung cancer. Presenting the study results at a recent medical meeting, researchers reported a substantial reduction in the risk of death by more than a third.

The comparative study involved 532 patients in China with stages 3 or 4 non-small cell lung cancer. All participants received chemotherapy alongside either ivonescimab or Tevimbra. Notably, those treated with ivonescimab, a bispecific antibody, lived for an average of 27.9 months compared to 23.7 months for those on Tevimbra. This new medication targets both PD-1 and VEGF proteins involved in cancer development.

While the trial indicates a step forward in cancer therapy, questions about its applicability to global populations remain. Dr. David Spigel, Nashville's Sarah Cannon Research Institute's chief medical officer, expressed cautious optimism. With ongoing global trials against Merck's Keytruda, the scientific community awaits further results that could set a new benchmark in lung cancer treatment.